Thierry Jean

Anceris SA specializes in developing therapeutic products for treatment of cancer. The company was founded in February 2000 and is headquartered in Paris, France.

SpinX designs and develops products which exploit its innovative adaptive microfluidics technology. The firm's platform offers a fully integrated solution which drastically reduces manual work, while avoiding complex and costly robotics, and can be used in a wide variety of applications, from drug discovery to consumer diagnostics. The reduced consumption of samples, reagents and other consumables enables increased throughput and results in significant cost savings. Additionally, the platform enables sophisticated interleaved liquid handling and detection steps not possible with other systems. SpinX is an international, multidisciplinary - but highly focused - team with world-class competences in microfludics, opto-electronics, molecular biology, biochemistry and software. The founders of SpinX Technologies, Bart Van de Vyver, Ph.D and Piero Zucchelli, Ph.D., worked together for 10 years on various research projects at CERN, the European Organization for Nuclear Research. They have conducted leading-edge academic research in particle physics and instrumentation and managed numerous state-of-the-art research projects. The SpinX Board of Directors and Advisory Board include experts from Europe and the United States, from a variety of backgrounds and disciplines covering drug discovery, diagnostics, microfluidics and physics.

Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France.